Comparison of Performance Characteristics of Three Real-Time Reverse Transcription-PCR Test Systems for Detection and Quantification of Hepatitis C Virus by Sabato, M. F. et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2007, p. 2529–2536 Vol. 45, No. 8
0095-1137/07/$08.000 doi:10.1128/JCM.00058-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Comparison of Performance Characteristics of Three Real-Time
Reverse Transcription-PCR Test Systems for Detection
and Quantification of Hepatitis C Virus
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We evaluated the performance characteristics of three real-time reverse transcription-PCR test systems for
detection and quantification of hepatitis C virus (HCV) and performed a direct comparison of the systems on
the same clinical specimens. Commercial HCV panels (genotype 1b) were used to evaluate linear range,
sensitivity, and precision. The Roche COBAS TaqMan HCV test for research use only (RUO) with samples
processed on the MagNA Pure LC instrument (Roche RUO-MPLC) and Abbott analyte-specific reagents
(ASR) with QIAGEN sample processing (Abbott ASR-Q) showed a sensitivity of 1.0 log10 IU/ml with a linear
dynamic range of 1.0 to 7.0 log10 IU/ml. The Roche ASR in combination with the High Pure system (Roche
ASR-HP) showed a sensitivity of 1.4 log10 IU/ml with a linear dynamic range of 2.0 to 7.0 log10 IU/ml. All of
the systems showed acceptable reproducibility, the Abbott ASR-Q being the most reproducible of the three
systems. Seventy-six clinical specimens (50 with detectable levels of HCV RNA and various titers and geno-
types) were tested, and results were compared to those of the COBAS Amplicor HCV Monitor v2.0. Good
correlation was obtained for the Roche RUO-MPLC and Abbott ASR-Q (R2  0.84 and R2  0.93, respectively),
with better agreement for the Abbott ASR-Q. However, correlation (R2  0.79) and agreement were poor for
Roche ASR-HP, with bias relative to concentration and genotype. Roche ASR-HP underestimated HCV RNA
for genotypes 3 and 4 as much as 2.19 log10 IU/ml. Our study demonstrates that Roche RUO-MPLC and Abbott
ASR-Q provided acceptable results and agreed sufficiently with the COBAS Amplicor HCV Monitor v2.0.
Hepatitis C virus (HCV) is still a major health care problem
worldwide, including the United States. It is estimated that
more than 170 million people worldwide are infected with
HCV. HCV is one of the leading indications for liver trans-
plantation in the United States (11). Prospective studies have
shown that 60 to 85% of HCV-infected individuals develop
chronic disease. Current recommendations for treatment are
combination therapy with pegylated interferon and ribavirin
(18). Treatment guidelines and monitoring the response to
therapy rely heavily on viral load testing and genotype infor-
mation. Genotyping should be performed before starting
treatment to determine duration of treatment and dosage of
ribavarin and also to provide prognostic information. The
recommended durations of combination therapy are 24 weeks
for genotypes 2 and 3 and 48 weeks for genotypes 1, 4, and 6
(18). Responses to treatment vary greatly, from approximately
40% for those infected with HCV genotypes 1 and 4 to about
80% for those infected with HCV genotypes 2 and 3.
Quantitative testing should be performed by methods with a
wide enough dynamic range for accurate assessment of both
pretreatment viral loads as well as an early virologic response,
which is defined as a fall in the HCV RNA levels by at least 2
log10 units or to an undetectable level at week 12 of treatment.
Currently, the best indicator of effective treatment is a sus-
tained virologic response (SVR), defined by the absence of
detectable HCV RNA in the serum when determined 6 months
after the end of treatment. A sensitive method with a low limit
of detection of 50 IU/ml or less should be used to assess SVR
(18).
A variety of assays are commercially available to detect and
quantify HCV RNA. They are based on three specific meth-
odologies: PCR, transcription-mediated amplification (TMA)
and the branched-DNA technique (4, 5, 15, 20). The most
commonly used PCR-based assay for HCV quantification is
the COBAS Amplicor HCV Monitor v2.0, with a lower limit of
quantification of 600 IU/ml, which is inadequate to define an
end-of-treatment response or SVR. Moreover, since this assay
has an upper limit of quantification of 800,000 IU/ml, samples
with baseline viral loads greater than the upper limit of quan-
tification have to be diluted and retested to determine an early
virologic response (5, 19, 27). The Versant HCV RNA v3.0
(Bayer HealthCare, Tarrytown, NY) uses branched-DNA
technology for quantification and has a linear dynamic range of
4.1 log10 with a lower limit of quantification of 615 IU/ml,
which is also inadequate for end-of-treatment assessments (5,
10, 21), making it necessary to use another method for evalu-
ation of SVR at the end of treatment.
The advent of real-time reverse transcription-PCR (RT-
PCR) combines high analytical sensitivity with wider dynamic
range of quantification in a single platform, eliminating the
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need for separate quantitative and qualitative assay formats to
meet the NIH guidelines (6, 12, 16, 18, 26). There are currently
on the market three different products for HCV detection and
quantification by real-time RT-PCR: the COBAS TaqMan
HCV ASR, the COBAS TaqMan HCV test, and the HCV
quantification ASR.
The COBAS TaqMan HCV test (Roche RUO; Roche Mo-
lecular Systems, Inc., Branchburg, NJ) is a real-time nucleic
acid amplification assay for detection and quantification of
HCV RNA in human serum or plasma. Roche markets this test
as a research-use-only (RUO) test, and it is comprised of two
products, the High Pure system viral nucleic acid kit for man-
ual extraction of RNA (HP; Roche Molecular Systems) and
the COBAS TaqMan HCV test kit, which can be purchased
separately. Automated sample preparation is also suitable with
the MagNA Pure LC instrument (MPLC; Roche Applied Sci-
ence, Indianapolis, IN). The FDA considers RUO products to
be products that are in the laboratory research phase of de-
velopment with potential usefulness that can be adapted to
clinical testing. The reagents in an RUO test are calibrated by
the manufacturer and come with additional controls and in-
structions for use. Calculation of the HCV RNA titer is based
upon an external standard curve in the presence of an internal
control. This assay has been developed for use with the
COBAS TaqMan 48 analyzer (CTM48; Roche Molecular
Systems).
There are also on the market HCV analyte-specific reagents
(ASRs) for HCV real-time RT-PCR, the ASR version of the
TaqMan HCV test (Roche ASR; Roche Molecular Systems)
and the HCV quantification ASR (Abbott ASR; Abbott Diag-
nostics, Abbott Park, IL). The FDA considers ASRs as build-
ing blocks of laboratory-developed tests used exclusively by the
laboratory that purchases the product. Under Clinical Labora-
tory Improvement Amendments regulations, the clinical labo-
ratories are required to develop and maintain the analytical
performance characteristics of the test in which the ASR is
used and to report the test results with a standard disclaimer.
These reagents and tests potentially offer many advantages
over current commercially available ones, including expanded
dynamic range, improved sensitivity and increased automation,
high throughput, and decreased turnaround time. Currently,
there are a limited number of published peer-reviewed studies
evaluating the performance characteristics of these reagents
and platforms (1, 3, 6, 8). Moreover, there are no published
data comparing these reagents and platforms using the same
clinical specimens.
Three different test systems were evaluated in this study,
using HCV RNA reference materials in which certain extrac-
tion methods were combined with certain real-time RT-PCR
reagents: (i) the COBAS TaqMan HCV ASR with manual
sample preparation with the Roche High Pure system (Roche
ASR-HP), (ii) the COBAS TaqMan HCV test with automated
sample preparation on the MPLC instrument (Roche RUO-
MPLC), and (iii) the HCV quantification ASR with manual
sample preparation with the QIAamp viral RNA Mini kit (Ab-
bott ASR-Q).
We chose to combine the Roche High Pure system with the
TaqMan HCV ASR to evaluate the Roche real-time reagents
along with a Roche manual sample processing method that
might be useful for a clinical laboratory to replace the COBAS
Monitor in routine diagnostic testing. We combined the Roche
MagNA Pure sample preparation with the TaqMan HCV
RUO because implementation of automated sample process-
ing might be beneficial for clinical laboratories with increasing
numbers of samples. The TaqMan HCV RUO became avail-
able at the time we performed the study and does not require
external calibration, which allows for standardization and
fewer requirements by the laboratories. We also combined the
QIAGEN viral RNA Mini kit manual extraction method with
the Abbott ASR based on recommendations provided by con-
sultants that had evaluated this system in their laboratories
with accurate results and also based on our experience using
this extraction method for other clinical testing.
After performing the evaluation of these systems, we ana-
lyzed clinical specimens that were previously tested in our
laboratory by the COBAS Amplicor HCV Monitor v2.0 test.
We compared the HCV RNA results of the real-time RT-PCR
systems with the COBAS Monitor results for correlation and
agreement and to evaluate performance for quantification of
different genotypes.
MATERIALS AND METHODS
HCV reference material. Two commercially available panels of HCV genotype
1b standards calibrated against the WHO International Standard for HCV RNA
were used for linearity and sensitivity studies: (i) the OptiQuant HCV RNA
(Acrometrix Corp., Benicia, CA) with seven members at 5,000,000, 500,000,
50,000, 5,000, 500, 50, and 0 IU/ml and associated dilutions (25, 10, and 5 IU/ml);
and (ii) the HCV linearity panel (PHW804; BBI Diagnostics, MA) with six
members at 10,000,000, 1,000,000, 250,000, 110,000, 11,000 and 1,600 IU/ml and
three associated dilutions down to 1.6 IU/ml. In addition, three different HCV
RNA reference materials at 910,000, 5,000, and 100 IU/ml were used for eval-
uation of precision (Accurun reference no. 405, 305, and 306, respectively)
(Boston Biomedica, Inc., Boston, MA). The HCV RNA reference materials of
5,000 and 100 IU/ml were also used as positive controls in every run for the
Roche ASR. Calibration of the Roche ASR was performed with reference
materials of 910,000, 5,000 and 1,000 IU/ml, respectively. Dilutions were pre-
pared by using residual HCV-negative human plasma from a single plasmaphere-
sis patient that was stored at 70°C until analysis. The HCV RNA values in
IU/ml obtained by the manufacturer using the COBAS Amplicor HCV Monitor
v2.0 test were used as expected values to evaluate the performance characteris-
tics of the systems.
Clinical specimens. To evaluate quantitative correlation and performance
related to different genotypes, a total of 76 residual plasma specimens (50
specimens with detectable levels of various HCV RNA titers and genotypes,
except genotype 5, and 26 undetectable specimens) submitted to our laboratory
between January 2002 and September 2003 for routine quantitative HCV RNA
testing were retrospectively selected for this study. The group of well-character-
ized plasma specimens had HCV RNA titers ranging from 3.97 to 7.09 log10
IU/ml, as determined by COBAS Amplicor HCV Monitor test v2.0 (Roche
Diagnostics Corporation, Indianapolis, IN) performed according to the manu-
facturer’s instructions. Specimens with concentrations greater than 500,000
IU/ml (5.7 log10) were diluted 1:100 in HCV-negative plasma and retested (13,
14, 17). These specimens included 26 HCV genotype 1, 8 HCV genotype 2, 6
HCV genotype 3, 7 genotype 4, and 3 genotype 6, as determined by Innolipa
assay (Versant HCV genotype assay; Bayer Diagnostics, Tarrytown, NY) per-
formed according to the manufacturer’s instructions (13, 14, 17). Specimens were
stored at 70°C from 4 to 84 weeks following the COBAS Monitor testing. The
study was reviewed and approved by the Medical College of Virginia Institu-
tional Review Board.
Real-time RT-PCR test systems. (i) Roche RUO-MPLC system. HCV RNA
was isolated from a 500-l aliquot of each of the reference materials, controls,
and clinical specimens using the automated MPLC instrument with software
version 3.03 and a Roche total nucleic acid isolation kit (large volume; Roche
Applied Science, Indianapolis, IN). The manufacturer’s protocol was followed
with the following modifications. The HCV internal quantification standard (QS)
was added directly to the lysis/binding buffer in order to achieve full process
control. For processing of 24 samples, 104 l of the internal QS was added to
34.4 ml of MagNA Pure lysis/binding buffer and gently mixed prior to being
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dispensed into the appropriate MPLC reagent reservoir. After completion of
several washing steps, purified nucleic acids were eluted in 75 l of elution buffer
at elevated temperature.
The master mix was activated by the addition of 170 l of 50 mM manganese
acetate and used within 60 min of preparation. Fifty microliters each of samples
from reference materials, controls, and clinical specimens was combined with 50
l of master mix and processed for amplification and detection using the COBAS
TaqMan 48 analyzer according to the manufacturer’s instructions with a single
lot of reagent throughout the study. The COBAS TaqMan 48 instrument with
Amplilink software v3.0.1 (Roche Molecular Systems) automatically determines
the HCV titer for each sample and control based upon an external standard
curve with the calibration coefficients that are specific for each lot of reagents.
(ii) Abbott ASR-Q system. HCV RNA was extracted from 220-l aliquots each
of reference material and controls using the QIAamp viral RNA Mini kit
(QIAGEN, Valencia, CA). The extraction was done per the manufacturer’s
instructions with the following modifications. First, 15.5 l of HCV RNA ASR
(Abbott Diagnostics, Abbott Park, IL) with an initial concentration of 4.38  106
IU/ml was added to the lysis buffer containing carrier RNA. The extracted RNA
was then eluted in 80 l of elution buffer. The Abbott internal QS (HCV RNA
ASR) is an armored RNA that is added to the lysis buffer to prevent degradation.
HCV RNA ASR contains RNA sequences complementary to the primers used
to amplify HCV and an intervening scrambled sequence that is used to detect the
HCV RNA ASR during the real-time RT-PCR. HCV RNA ASR is used for
quantification of HCV RNA and to correct for the presence of reaction inhibi-
tors and other variables that can affect the efficiency of real-time PCR.
Fifty microliters each of samples from reference materials and controls was
loaded into a 96-well optical reaction plate containing 50 l of reaction mixture
in each well, and the real-time RT-PCR was carried out on an ABI Prism 7000
sequence detection system (Applied Biosystems, Foster City, CA) using the
following thermal cycling parameters: a first stage of activation of AmpErase
uracil-N-glycosylase (4 min at 50°C), followed by an RT (30 min at 60°C) and 50
PCR cycles of 91°C for 15 s and 60°C for 1 min. Sequence Quantification
Software v2.0 (Abbott Diagnostics, Abbott Park, IL) was used to calculate the
HCV RNA concentration in the samples by comparing the signals generated by
the target and the internal calibrator.
Clinical specimens were analyzed next, following the aforementioned opti-
mized protocol to assess correlation.
(iii) Roche ASR-HP system. HCV RNA was isolated from 500 l each of the
reference material and controls using the manual High Pure system viral nucleic
acid kit procedure (Roche Applied Science, Indianapolis, IN). Sample prepara-
tion was done according to the manufacturer’s instructions, adding the appro-
priate volume of HCV internal QS RNA to each specimen so that the final
concentration of the QS after HCV RNA isolation was approximately 1,100
copies per reaction tube. Nucleic acids were eluted from glass fiber particles with
75 l of elution buffer.
Working master mix was prepared by combining manganese (170 l) and ASR
master mix reagents (1.4 ml). The working master mix (50 l) was added to each
K-tube in the K-carrier, followed by 50 l of each test sample. Samples were
processed for amplification and detection on the COBAS TaqMan 48 analyzer
using the following thermal cycling parameters: two precycles of 5 min at 50°C
and 30 min at 59°C and 25 cycles of 15 s at 95°C and 25 s at 58°C followed by 25
cycles of 15 s at 91°C and 25 s at 58°C and a postcycle hold at 40°C. A cycle delay
of 25 s was set up during the annealing steps. The TaqMan HCV ASR requires
user calibration with each new lot of reagents. For this study, one lot of Roche
ASR reagents was used and calibration was performed using commercially avail-
able reference materials. The HCV QS was introduced during sample prepara-
tion into reference materials with known concentrations of HCV RNA genotype
1b (910,000, 5,000, and 1,000 IU/ml previously assigned by the commercial
vendor against the WHO 1st International Standard for HCV RNA). Six repli-
cates of each reference material were then processed to isolate HCV and HCV
QS RNA as mentioned above. The resulting samples were amplified and de-
tected in the COBAS TaqMan analyzer. The threshold values for both HCV and
HCV QS obtained for each calibrator were saved and exported as text files. The
text files were imported into ASR external calibration software (Roche Molec-
ular Systems, Inc., version 2.1) to derive three coefficients. The entire process was
repeated three times, and calibration coefficients were calculated for each run.
The average of each calibration coefficient defined the calibration curve for the
ASR-specific lot, and they were used in the calculation of sample HCV RNA
concentrations.
Clinical specimens were next tested for correlation study following the afore-
mentioned protocol with the same TaqMan HCV ASR lot number and quanti-
fied using those calibration coefficients.
Quantitative correlation and genotype performance. The data obtained from
the analysis of the 76 clinical specimens by the real-time RT-PCR systems were
compared with previous results of HCV viral load by COBAS Amplicor HCV
Monitor v2.0 assay. Correlation, agreement, and performance related to geno-
typic differences between the two methods were assessed. The difference be-
tween the log10 HCV RNA IU/ml results obtained from the real-time RT-PCR
and the COBAS Monitor were plotted against their average in log10 HCV RNA
IU/ml to determine the agreement between the two methods. Since, the true
value was not determined by a reference method, the average of the two mea-
surements was the best alternative. The limits of agreement for the real-time
RT-PCR HCV systems were also calculated. Performance with relation to ge-
notype for the Roche ASR-HP was evaluated, and the quantification differences
between both assays (Roche ASR-HP versus COBAS Monitor) were plotted
against their average to estimate the genotype bias.
Statistical analysis. HCV concentrations were log10 transformed for analysis.
The linear range was examined by plotting the data and comparing them to a line
of equality. Correlation coefficients and linear regression analysis were done in
scatter plots for log-transformed HCV RNA levels using Microsoft Excel (Mi-
crosoft Office 2000; Microsoft Corp., Redmond, WA). Agreement between the
COBAS Monitor and the real-time RT-PCR systems was determined by Bland-
Altman plot (2). Potential differences in target amplification efficiency were
examined by comparing the slopes of the linear regression lines.
RESULTS
Linearity of the real-time RT-PCR systems. The HCV RNA
reference materials of genotype 1b were extracted and run in
triplicates on 3 different days by Roche RUO-MPLC, Abbott
ASR-Q, and Roche ASR-HP to establish the linear range of
the systems. Data detailing the results are presented in Fig. 1.
Results were plotted using the log-transformed values of the
nominal HCV RNA input concentrations and the log-trans-
formed values of the HCV RNA measured concentrations and
analyzed using linear regression.
Roche RUO-MPLC. Regression analysis showed a linear
correlation between the Roche RUO-MPLC and the expected
HCV RNA values (R2  0.994) (Fig. 1A). The slope of the
curve was 0.896, but it is interesting to note that for values
2.70 log10 IU/ml, the mean measured values were lower than
nominal values by about 0.23 log10 IU/ml and the mean mea-
sured values were 0.23 log10 IU/ml higher than the nominal
values at concentrations 2.70 log10 IU/ml. The Roche RUO-
MPLC was linear in the full range tested (1.0 to 7.0 log10
IU/ml), with high reproducibility and a mean coefficient of
variation (CV) of 5.34% in log10 IU/ml. These concentrations
met the criterion of acceptable precision and trueness (stan-
dard deviation [SD],  0.25) used to define the lower and
higher limits of quantification for this particular assay.
Abbott ASR-Q. Linear correlation between the Abbott
ASR-Q and the expected HCV RNA values was obtained
(R2  0.995) with a slope close to 1.00 (Fig. 1B). The HCV
RNA measured concentrations were consistently lower than the
nominal concentrations of 0.26 log10 IU/ml as an average.
The assay was linear between 1.0 and at least 7.0 log10 IU/ml.
The Abbott ASR-Q lower and higher limits of quantification
were established at those concentrations since they met the
criterion of acceptable precision and trueness (SD, 0.25).
Roche ASR-HP. The Roche ASR-HP showed a linear cor-
relation between nominal and measured concentrations (R2 
0.985) (Fig. 1C). The slope of the linear regression line was
close to 1.0, and HCV RNA results were lower than the nom-
inal value of 0.02 log10 IU/ml as an average. The assay was
linear and very reproducible between 2.0 and at least 7.0 log10
IU/ml, with an average CV of 2.99% in log10 IU/ml. The lower
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and higher limits of quantification were determined at those
values, respectively (SD, 0.25).
Precision. Reproducibility was evaluated by using three dif-
ferent levels of reference material of genotype 1b with 910,000,
5,000, and 100 IU/ml HCV RNA levels that were run in du-
plicate in six runs performed on 6 different days. The three
systems showed acceptable reproducibility, with interassay CV
ranging from 2.46% to 9.29% in log10 IU/ml for the higher
level and the lower level of reference materials, respectively.
The Abbott ASR-Q was the most reproducible of the three
systems.
Analytical sensitivity. Six serial dilutions (500, 100, 50, 25,
10, and 5 IU/ml) of a reference material with 5,000 HCV RNA
IU/ml (NAP; Acrometrix, Benicia, CA) were run in duplicate
on 3 different days to determine the sensitivity of the real-time
RT-PCR systems. The Roche RUO-MPLC and Abbott ASR-Q
systems were able to detect all six replicates with 10 HCV RNA
IU/ml (1.0 log10 IU/ml), and the Roche ASR-HP system was
able to detect all six replicates with 25 HCV RNA IU/ml (1.4
log10 IU/ml).
Quantitative correlation of the real-time RT-PCR systems
and the COBAS Monitor. Results obtained from the analysis
of the 76 clinical specimens by real-time RT-PCR systems were
compared with previous results obtained from COBAS Am-
plicor HCV Monitor v2.0 assay. The clinical sensitivity and
specificity of the TaqMan systems were 100%, respectively; 26
of 76 clinical specimens with undetectable results by COBAS
Monitor were also undetectable by the TaqMan systems, and
50 of 76 clinical specimens with detectable results by COBAS
Monitor were also detectable by the TaqMan systems. Quan-
titative correlations between the COBAS Monitor and the
real-time RT-PCR systems were established in the 50 clinical
specimens with detectable HCV RNA values by both methods,
and the results are plotted in Fig. 2. Mean viral load values, SD
of the mean, and quantification differences between the real-
time RT-PCR systems and COBAS Monitor were also calcu-
lated by genotype and are represented in Table 1.
Roche RUO-MPLC with COBAS Monitor. Comparison of
Roche RUO-MPLC with COBAS Monitor showed a good
correlation by linear regression analyses (R2  0.840; P 
0.0001) with a slope close to 1 (Fig. 2). The Roche RUO-
MPLC results were consistently lower than the COBAS Mon-
itor results. Genotype 3 samples showed a slightly higher de-
gree of underestimation compared to genotypes 1, 2, and 4
(Table 1).
Abbott ASR-Q with COBAS Monitor. Comparison of Ab-
bott ASR-Q with COBAS Monitor showed a strong correla-
tion by linear regression analyses (R2  0.925; P  0.0001)
independent of genotype. The slope of the curve was close to
1, with HCV RNA results being slightly lower than COBAS
Monitor results for most of the samples (Fig. 2 and Table 1).
Roche ASR-HP with COBAS Monitor. Poor correlation was
obtained when comparing Roche ASR-HP results with those
from the COBAS Monitor (R2  0.788; P  0.0001) (Fig. 2).
Characteristics of the regression line included a slope of 1.25
and a y intercept of 1.73. Data analysis demonstrated that
Roche ASR-HP results depended on HCV RNA concentra-
tion and genotype (Table 1); hence, a detailed analysis for each
genotype was performed for this assay.
To determine whether genotype-specific quantification bias
occurs in the Roche ASR-HP, the 50 positive HCV RNA
samples were analyzed by genotype and compared to the
COBAS Monitor results. Good correlation was obtained for
HCV genotype 1 (R2  0.940; P  0.0001). However, the slope
FIG. 1. Linearity of the real time RT-PCR systems. Linear range
was determined by regression analysis using the expected HCV RNA
concentrations and the corresponding test results. Each point repre-
sents the mean log10 HCV IU/ml of three replicates tested on 3 dif-
ferent days. The dashed line represents equality.
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of the curve was 1.36, with an overestimation of the HCV RNA
concentrations by the Roche ASR-HP for samples with
COBAS Monitor results higher than 6.4 log10 IU/ml and un-
derestimation of the HCV RNA concentrations for samples
with lower than 5.30 log10 IU/ml by COBAS Monitor. Four of
26 samples had HCV RNA results lower than 0.5 log10 IU/ml
compared to COBAS Monitor. Regression analysis for geno-
type 2 (R2  0.802; P  0.005) and genotype 4 (R2  0.700;
P  0.05) showed poor correlation. Two of the eight genotype
2 samples and four of the seven genotype 4 samples had HCV
RNA results of about 1.0 log10 IU/ml lower than COBAS
Monitor results. There was no correlation for genotype 3 (R2 
0.495; P  0.12), and four of six samples showed an underes-
timation by 1.24 to 2.19 log10 IU/ml using the Roche ASR-HP
system. Regression analysis for genotype 6 was not performed
due to the small number of samples. Quantification differences
between the Roche ASR-HP and the COBAS Monitor were
also plotted against their average to estimate the genotype bias
(Fig. 3).
Agreement between the real-time RT-PCR systems and the
COBAS Monitor. A Bland and Altman plot was used to de-
termine the agreement between the Roche RUO-MPLC, Ab-
bott ASR-Q, and Roche ASR-HP systems and the COBAS
Monitor. Using this method, the differences between the real-
time RT-PCR systems and the COBAS Monitor were plotted
against the averages of the two techniques.
Roche RUO-MPLC with COBAS Monitor. The Roche
RUO-MPLC results were consistently lower than those of the
COBAS Monitor. The mean difference between values (Roche
RUO MPLC values  COBAS Monitor values) was 0.49
log10  0.22, with limits of agreement (mean difference  2
SD) of 0.05 and 0.93 log10 IU/ml. No bias in relation to
concentration was observed (Fig. 4A).
Abbott ASR-Q with COBAS Monitor. Results from the Ab-
bott ASR-Q were in good agreement with the COBAS Mon-
itor. The mean difference between the real-time RT-PCR val-
ues and the COBAS Monitor values was 0.20 log10  0.24,
with limits of agreement of 0.29 and 0.69 log10 IU/ml, and
more than 95% of the differences fell within these limits. In
concordance with Roche RUO-MPLC, no bias in relation to
concentration was observed (Fig. 4B).
Roche ASR-HP with COBAS Monitor. The agreement be-
tween Roche ASR-HP and COBAS Monitor was poor, with a
mean difference of 0.33 log10  0.68 between the results
(Roche ASR-HP and COBAS Monitor). The differences tend
to be negative for samples with viral load values of 5.0 log10
IU/ml, equally distributed around the mean difference for sam-
ples with viral load values between 5.0 and 6.4 log10 IU/ml, and
positive for samples with viral load values of 6.4 log10 IU/ml
(Fig. 4C).
As previously described, a bias related to genotype was
found. Agreement plots between the Roche ASR-HP and the
COBAS Monitor for genotypes 1 to 4 are shown in Fig. 3.
DISCUSSION
HCV RNA quantification is an essential tool for manage-
ment of acute and chronic hepatitis C. Thus, the method used
to quantify HCV RNA should be reliable across all the differ-
ent HCV genotypes and have a high sensitivity and a wide
dynamic range.
Our evaluation of the performance characteristics of RT-
PCR systems clearly demonstrated the advantages of using
real-time RT-PCR in monitoring HCV patients. The Roche
RUO-MPLC and Abbott ASR-Q were demonstrated to be
accurate and reliable systems capable of providing quantitative
results in a single test that meets the current NIH guidelines
for treatment decisions and therapy monitoring.
Our analytical data suggest that the Roche RUO-MPLC and
Abbott ASR-Q systems are very sensitive, detecting 100% of
the replicates with 1.0 log10 HCV RNA IU/ml. Even though
FIG. 2. Correlation of results for the real-time RT-PCR systems
and COBAS Amplicor HCV Monitor v2.0. The dashed line indicates
the line of equality.
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the Abbott ASR-Q system uses roughly half the starting sam-
ple volume, it was also able to detect 1.0 log10 HCV RNA
IU/ml, similar to the Roche RUO-MPLC. In addition, they
remained linear to at least 7.0 log10 HCV RNA IU/ml. Our
study was limited to the analysis of reference material ranging
from 1.1  107 IU/ml to undetectable and clinical samples with
a higher titer of 1.23  107 IU/ml. We did not evaluate the
higher reportable range of the COBAS TaqMan HCV test
(2  108 IU/ml) as defined by the assay’s manufacturer. The
Roche RUO-MPLC results obtained from our study were con-
sistent with those recently reported by Germer et al. with
respect to the limit of detection and linear range (8). The limit
of detection and linear range of the Roche RUO-MPLC and
Abbott ASR-Q in our study were also in concordance with a
recent study by Caliendo et al. (3), even though the authors
used the QIAGEN MiniElute system for nucleic acid extrac-
tion. Both systems provided sensitivity equivalent to that of the
commercially available HCV RNA qualitative assays (Ampli-
cor HCV; Roche Diagnostics, Indianapolis, IN; and TMA-
based Versant; Bayer HealthCare, Berkley, CA) and a higher
dynamic range than the quantitative available assays (10). The
combinations of high analytical sensitivity with a wider dy-
namic range of quantification in a single platform eliminate the
need for multiple testing. The increased sensitivity of these
systems could be important in the management of HCV-in-
fected patients, since the increased sensitivity of transcription-
mediated amplification has been shown to improve the detec-
tion of extremely low levels of HCV RNA in end-of-treatment
specimens and improve the prediction of treatment failure or
virologic relapse in patients receiving anti-HCV therapy (9,
24). The performance of the Roche ASR-HP with respect to
the reference materials with genotype 1b showed lower sensi-
TABLE 1. Quantitative values by HCV genotype for real-time RT-PCR systems in 50 clinical specimens
HCV
genotype
Genotype quantification in mean log10 IU/ml (SD)
Quantification difference















1 5.43 (1.08) 5.03 (1.00) 5.23 (1.23) 5.35 (1.51) 0.4 0.2 0.08
2 5.80 (1.05) 5.35 (1.02) 5.64 (0.88) 5.61 (1.47) 0.45 0.16 0.19
3 5.23 (1.05) 4.62 (0.89) 5.01 (0.99) 3.99 (0.89) 0.61 0.22 1.24
4 5.69 (0.36) 5.22 (0.38) 5.4 (0.34) 5.02 (0.50) 0.47 0.29 0.67
a Differences in quantification between the real-time RT-PCR systems and COBAS Amplicor Monitor show some trends in the performance of the systems, especially
when broken down by genotype.
FIG. 3. Differences in quantification between Roche ASR-HP and COBAS Monitor in log10 HCV RNA IU/ml for genotypes 1 to 4.
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tivity (1.4 log10 IU/ml) than the Roche RUO-MPLC and Ab-
bott ASR-Q, with a linear dynamic range of 2.0 to 7.0 log10
HCV RNA IU/ml.
The Abbott ASR-Q was the most reproducible of the three
systems tested. The Roche RUO-MPLC and the Roche
ASR-HP were also quite reproducible for reference materials
with HCV RNA values greater than 2.0 log10 IU/ml.
In dynamic range experiments using reference material of
HCV genotype 1b, all three systems gave viral load values
within 0.5 log10 IU/ml for all concentrations in the respective
linear range of the systems. This level of agreement was re-
markable, given that the systems had different extraction meth-
ods, cycling parameters, and instrumentations. In contrast,
greater variability in quantification between the different sys-
tems was observed when clinical specimens were tested for
correlation and performance with respect to different geno-
types. The Roche RUO-MPLC and Abbott ASR-Q results
from clinical specimens were in good correlation with those of
COBAS Amplicor HCV Monitor v2.0. Results were lower than
those of the COBAS Monitor for most of the samples tested,
and no bias in relation to concentration was observed. There
were no substantial differences in quantification among the
various HCV genotypes, except for genotype 3 samples that
were slightly underestimated by Roche RUO-MPLC. The av-
erage differences in quantification were less than 0.5 log10
IU/ml (within threefold), which are generally considered ac-
ceptable when comparing different methods for HCV viral
load measurement (25), with a better level of agreement for
the Abbott ASR-Q. It was recently noted that HCV Monitor
v2.0 overestimated an international standard concentration by
approximately 0.49 log10 IU/ml (22). The authors attributed
the overestimation to an erroneous assignment of the number
of IU/ml to the HCV RNA concentration of the QS. However,
there is no “gold standard” quantitative assay for these types of
studies and, for the purposes of this analysis, trends in viral
load were more important than absolute quantification.
Comparison of Roche ASR-HP system with the COBAS
Monitor in 50 clinical specimens with various HCV RNA titers
and genotypes showed poor correlation and poor agreement
between the two methods with bias relative to concentration
and genotype. A significant underestimation of the HCV RNA
levels for some samples with genotype 2 and most of the
samples with genotypes 3 and 4 was observed. These results are
consistent with those described by Sarrazin et al. and Gelder-
blom et al. (7, 23) using the High Pure system in combination
with the COBAS TaqMan HCV RUO test. In contrast, For-
man and Valsamakis and Barbeau et al. (1, 6) observed similar
amplification efficiencies for genotypes 1 to 4 when QIAGEN
manual and automated extraction methods and automated ex-
traction on the MPLC instrument, respectively, were used in
combination with the Roche ASR. According to Roche, the
COBAS TaqMan ASR and RUO tests are equipped with the
same primers and probes; therefore, genotype differences may
be caused by components of the High Pure system (for exam-
ple, buffer solutions) that might influence the unfolding of the
HCV RNA, as was recently described by Gelderblom et al. (7).
Although certain parts of the 5	 untranslated region (5	UTR)
are highly conserved among genotypes, other parts of the
5	UTR and flanking regions are not. The tertiary and quater-
nary structures of the HCV RNA may differ among genotypes,
FIG. 4. Differences in log10 HCV RNA between the real-time RT-
PCR systems and COBAS Monitor plotted against the averages of the
two techniques. GENO, genotype.
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and sequence differences outside the 5	UTR may influence its
folding and unfolding. Incomplete unfolding may (i) comprise
binding of HCV RNA to glass fiber and cause loss of HCV
RNA during the HP extraction and/or (ii) reduce binding of
the primers and probe to the highly conserved 5	UTR of the
HCV genome, both resulting in underestimation of HCV RNA
in the specimen. Further studies are needed to assess the
reasons for underestimation of some but not all of the samples
with genotypes 2, 3, and 4.
In summary, this study describes the performance of three
real-time RT-PCR systems and compares it with results ob-
tained from the COBAS Monitor assay. Although the Abbott
ASR-Q system performed slightly better than the Roche
RUO-MPLC, especially in quantification of HCV genotype 3,
both systems performed very well and agreed sufficiently with
the established COBAS Amplicor HCV Monitor v2.0.
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